230 related articles for article (PubMed ID: 30989330)
1. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Crescenzo R; Mamolo C; Reisman A; Hochhaus A; Brümmendorf TH;
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1589-1599. PubMed ID: 30989330
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
[TBL] [Abstract][Full Text] [Related]
4. Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
Brümmendorf TH; Gambacorti-Passerini C; Bushmakin AG; Cappelleri JC; Viqueira A; Reisman A; Isfort S; Mamolo C
Ann Hematol; 2020 Jun; 99(6):1241-1249. PubMed ID: 32307568
[TBL] [Abstract][Full Text] [Related]
5. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
6. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
[TBL] [Abstract][Full Text] [Related]
7. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
Brümmendorf TH; Cortes JE; Milojkovic D; Gambacorti-Passerini C; Clark RE; le Coutre P; Garcia-Gutierrez V; Chuah C; Kota V; Lipton JH; Rousselot P; Mauro MJ; Hochhaus A; Hurtado Monroy R; Leip E; Purcell S; Yver A; Viqueira A; Deininger MW;
Leukemia; 2022 Jul; 36(7):1825-1833. PubMed ID: 35643868
[TBL] [Abstract][Full Text] [Related]
8. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
[TBL] [Abstract][Full Text] [Related]
9. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
[TBL] [Abstract][Full Text] [Related]
10. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
Cortes JE; Kim DW; Kantarjian HM; Brümmendorf TH; Dyagil I; Griskevicius L; Malhotra H; Powell C; Gogat K; Countouriotis AM; Gambacorti-Passerini C
J Clin Oncol; 2012 Oct; 30(28):3486-92. PubMed ID: 22949154
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
Hino M; Matsumura I; Fujisawa S; Ishizawa K; Ono T; Sakaida E; Sekiguchi N; Tanetsugu Y; Fukuhara K; Ohkura M; Koide Y; Takahashi N
Int J Hematol; 2020 Jul; 112(1):24-32. PubMed ID: 32279228
[TBL] [Abstract][Full Text] [Related]
12. Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
Garrett M; Knight B; Cortes JE; Deininger MW
Cancer Med; 2023 Sep; 12(17):17981-17992. PubMed ID: 37553873
[TBL] [Abstract][Full Text] [Related]
13. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
Kota V; Brümmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim DW; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
Leuk Res; 2021 Dec; 111():106690. PubMed ID: 34673442
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
Trask PC; Cella D; Besson N; Kelly V; Masszi T; Kim DW
Leuk Res; 2012 Apr; 36(4):438-42. PubMed ID: 22036634
[TBL] [Abstract][Full Text] [Related]
16. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Quintás-Cardama A; Kantarjian H; Cortes J
Drugs Today (Barc); 2012 Mar; 48(3):177-88. PubMed ID: 22462037
[TBL] [Abstract][Full Text] [Related]
17. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.
Hsyu PH; Mould DR; Upton RN; Amantea M
Cancer Chemother Pharmacol; 2013 Jan; 71(1):209-18. PubMed ID: 23070145
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]